Cargando…

Treatment of Lyme borreliosis

Borrelia burgdorferi sensu lato is the causative agent of Lyme borreliosis in humans. This inflammatory disease can affect the skin, the peripheral and central nervous system, the musculoskeletal and cardiovascular system and rarely the eyes. Early stages are directly associated with viable bacteria...

Descripción completa

Detalles Bibliográficos
Autores principales: Girschick, Hermann J, Morbach, Henner, Tappe, Dennis
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003502/
https://www.ncbi.nlm.nih.gov/pubmed/20067594
http://dx.doi.org/10.1186/ar2853
_version_ 1782193864348532736
author Girschick, Hermann J
Morbach, Henner
Tappe, Dennis
author_facet Girschick, Hermann J
Morbach, Henner
Tappe, Dennis
author_sort Girschick, Hermann J
collection PubMed
description Borrelia burgdorferi sensu lato is the causative agent of Lyme borreliosis in humans. This inflammatory disease can affect the skin, the peripheral and central nervous system, the musculoskeletal and cardiovascular system and rarely the eyes. Early stages are directly associated with viable bacteria at the site of inflammation. The pathogen-host interaction is complex and has been elucidated only in part. B. burgdorferi is highly susceptible to antibiotic treatment and the majority of patients profit from this treatment. Some patients develop chronic persistent disease despite repeated antibiotics. Whether this is a sequel of pathogen persistence or a status of chronic auto-inflammation, auto-immunity or a form of fibromyalgia is highly debated. Since vaccination is not available, prevention of a tick bite or chemoprophylaxis is important. If the infection is manifest, then treatment strategies should target not only the pathogen by using antibiotics but also the chronic inflammation by using anti-inflammatory drugs.
format Text
id pubmed-3003502
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30035022010-12-18 Treatment of Lyme borreliosis Girschick, Hermann J Morbach, Henner Tappe, Dennis Arthritis Res Ther Review Borrelia burgdorferi sensu lato is the causative agent of Lyme borreliosis in humans. This inflammatory disease can affect the skin, the peripheral and central nervous system, the musculoskeletal and cardiovascular system and rarely the eyes. Early stages are directly associated with viable bacteria at the site of inflammation. The pathogen-host interaction is complex and has been elucidated only in part. B. burgdorferi is highly susceptible to antibiotic treatment and the majority of patients profit from this treatment. Some patients develop chronic persistent disease despite repeated antibiotics. Whether this is a sequel of pathogen persistence or a status of chronic auto-inflammation, auto-immunity or a form of fibromyalgia is highly debated. Since vaccination is not available, prevention of a tick bite or chemoprophylaxis is important. If the infection is manifest, then treatment strategies should target not only the pathogen by using antibiotics but also the chronic inflammation by using anti-inflammatory drugs. BioMed Central 2009 2009-12-17 /pmc/articles/PMC3003502/ /pubmed/20067594 http://dx.doi.org/10.1186/ar2853 Text en Copyright ©2009 BioMed Central Ltd.
spellingShingle Review
Girschick, Hermann J
Morbach, Henner
Tappe, Dennis
Treatment of Lyme borreliosis
title Treatment of Lyme borreliosis
title_full Treatment of Lyme borreliosis
title_fullStr Treatment of Lyme borreliosis
title_full_unstemmed Treatment of Lyme borreliosis
title_short Treatment of Lyme borreliosis
title_sort treatment of lyme borreliosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003502/
https://www.ncbi.nlm.nih.gov/pubmed/20067594
http://dx.doi.org/10.1186/ar2853
work_keys_str_mv AT girschickhermannj treatmentoflymeborreliosis
AT morbachhenner treatmentoflymeborreliosis
AT tappedennis treatmentoflymeborreliosis